{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:00:07Z","timestamp":1779922807129,"version":"3.53.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This review will begin with a detail of the revision of the WHO classification, and pathological definitions of Burkitt lymphoma. Over the past several years, molecular understanding of Burkitt lymphoma has improved significantly. Using gene expression profiling, a genomic \u201csignature\u201d of Burkitt lymphoma may be identified, that has fidelity beyond c-myc expression, and the presence of the classical t(8;14). Then, evaluation and therapy of the adult patient with Burkitt lymphoma will be reviewed. Relatively few data exist on optimal therapy of the adult patient with Burkitt lymphoma. Principles of therapy should include high doses of alkylating agents, frequent administration of chemotherapy, and attention to central nervous system (CNS) prophylaxis with high doses of systemic chemotherapy, intrathecal therapy, or both. The outcome of adult patients with Burkitt lymphoma, particularly those over 40 years of age, is inferior to the outcome of younger patients, but may be improving over the past few years. Results from an international collaborative effort, which are helpful in evaluating results of Burkitt lymphoma therapy in adults, will be presented. HIV-associated Burkitt lymphoma, and elderly patients with Burkitt lymphoma, comprise special clinical situations that will be also covered in this review.<\/jats:p>","DOI":"10.1182\/asheducation-2008.1.341","type":"journal-article","created":{"date-parts":[[2008,12,11]],"date-time":"2008-12-11T15:12:58Z","timestamp":1229008378000},"page":"341-348","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":69,"title":["Burkitt Lymphoma in Adults"],"prefix":"10.1182","volume":"2008","author":[{"given":"Archibald S.","family":"Perkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111709210457900_R1","doi-asserted-by":"crossref","unstructured":"Coakley D. Denis Burkitt and his contribution to haematology\/oncology. Br J Haematol. 2006;135:17\u201325.","DOI":"10.1111\/j.1365-2141.2006.06267.x"},{"key":"2019111709210457900_R2","unstructured":"Brady G, MacArthur GJ, Farrell PJ. Epstein-Barr virus and Burkitt lymphoma. J Clin Pathol. 2007;60:1397\u20131402."},{"key":"2019111709210457900_R3","doi-asserted-by":"crossref","unstructured":"Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol. 2007;60:1365\u20131372.","DOI":"10.1136\/jcp.2007.051953"},{"key":"2019111709210457900_R4","doi-asserted-by":"crossref","unstructured":"Nakamura N, Nakamine H, Tamaru J, et al. The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement. Mod Pathol. 2002;15:771\u2013776.","DOI":"10.1097\/01.MP.0000019577.73786.64"},{"key":"2019111709210457900_R5","doi-asserted-by":"crossref","unstructured":"Leoncini L, Delsol G, Gascoyne RD, et al. Aggressive B-cell lymphomas: a review based on the workshop of the XI Meeting of the European Association for Haematopathology. Histopathology. 2005;46:241\u2013255.","DOI":"10.1111\/j.1365-2559.2005.02068.x"},{"key":"2019111709210457900_R6","doi-asserted-by":"crossref","unstructured":"Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt\u2019s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419\u20132430.","DOI":"10.1056\/NEJMoa055351"},{"key":"2019111709210457900_R7","doi-asserted-by":"crossref","unstructured":"Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt\u2019s lymphoma. N Engl J Med. 2006;354:2431\u20132442.","DOI":"10.1056\/NEJMoa055759"},{"key":"2019111709210457900_R8","doi-asserted-by":"crossref","unstructured":"Rodig SJ, Vergilio JA, Shahsafaei A, Dorfman DM. Characteristic expression patterns of TCL1, CD38, and CD44 identify aggressive lymphomas harboring a MYC translocation. Am J Surg Pathol. 2008;32:113\u2013122.","DOI":"10.1097\/PAS.0b013e3180959e09"},{"key":"2019111709210457900_R9","doi-asserted-by":"crossref","unstructured":"Bertrand P, Bastard C, Maingonnat C, et al. Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas. Leukemia. 2007;21:515\u2013523.","DOI":"10.1038\/sj.leu.2404529"},{"key":"2019111709210457900_R10","doi-asserted-by":"crossref","unstructured":"Le Gouill S, Talmant P, Touzeau C, et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24\/c-MYC rearrangement. Haematologica. 2007;92:1335\u20131342.","DOI":"10.3324\/haematol.11305"},{"key":"2019111709210457900_R11","doi-asserted-by":"crossref","unstructured":"Macpherson N, Lesack D, Klasa R, et al. Small noncleaved, non-Burkitt\u2019s (Burkitt-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol. 1999;17:1558\u20131567.","DOI":"10.1200\/JCO.1999.17.5.1558"},{"key":"2019111709210457900_R12","doi-asserted-by":"crossref","unstructured":"McClure RF, Remstein ED, Macon WR, et al. Adult B-cell lymphomas with Burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior. Am J Surg Pathol. 2005;29:1652\u20131660.","DOI":"10.1097\/01.pas.0000180442.87022.08"},{"key":"2019111709210457900_R13","doi-asserted-by":"crossref","unstructured":"Roberts RA, Sabalos CM, LeBlanc ML, et al. Quantitative nuclease protection assay in paraffin-embedded tissue replicates prognostic microarray gene expression in diffuse large-B-cell lymphoma. Lab Invest. 2007;87:979\u2013997.","DOI":"10.1038\/labinvest.3700665"},{"key":"2019111709210457900_R14","doi-asserted-by":"crossref","unstructured":"Kian TC, Miriam T, Richard Q, et al. Clinical characteristics, prognostic factors and outcomes of Burkitt lymphoma in adult Asians. Leuk Lymphoma. 2008;49:824\u2013827.","DOI":"10.1080\/10428190701882948"},{"key":"2019111709210457900_R15","doi-asserted-by":"crossref","unstructured":"Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101:3875\u20133876.","DOI":"10.1182\/blood-2002-09-2778"},{"key":"2019111709210457900_R16","doi-asserted-by":"crossref","unstructured":"Smeland S, Blystad AK, Kvaloy SO, et al. Treatment of Burkitt\u2019s\/Burkitt-like lymphoma in adolescents and adults: a 20-year experience from the Norwegian Radium Hospital with the use of three successive regimens. Ann Oncol. 2004;15:1072\u20131078.","DOI":"10.1093\/annonc\/mdh262"},{"key":"2019111709210457900_R17","doi-asserted-by":"crossref","unstructured":"Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001;97:2998\u20133003.","DOI":"10.1182\/blood.V97.10.2998"},{"key":"2019111709210457900_R18","doi-asserted-by":"crossref","unstructured":"Magrath IT, Haddy TB, Adde MA. Treatment of patients with high grade non-Hodgkin\u2019s lymphomas and central nervous system involvement: is radiation an essential component of therapy? Leuk Lymphoma. 1996;21:99\u2013105.","DOI":"10.3109\/10428199609067586"},{"key":"2019111709210457900_R19","doi-asserted-by":"crossref","unstructured":"Lacasce A, Howard O, Lib S, et al. Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004;45:761\u2013767.","DOI":"10.1080\/1042819031000141301"},{"key":"2019111709210457900_R20","doi-asserted-by":"crossref","unstructured":"Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13:1264\u20131274.","DOI":"10.1093\/annonc\/mdf253"},{"key":"2019111709210457900_R21","doi-asserted-by":"crossref","unstructured":"Rizzieri DA, Johnson JL, Niedzwiecki D, et al. Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004;100:1438\u20131448.","DOI":"10.1002\/cncr.20143"},{"key":"2019111709210457900_R22","doi-asserted-by":"crossref","unstructured":"Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87:495\u2013508.","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495"},{"key":"2019111709210457900_R23","doi-asserted-by":"crossref","unstructured":"van Imhoff GW, van der Holt B, MacKenzie MA, et al. Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. Leukemia. 2005;19:945\u2013952.","DOI":"10.1038\/sj.leu.2403733"},{"key":"2019111709210457900_R24","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Ciminello L, Kelly J, et al. Outcome of patients > age 40 with Burkitt lymphoma (BL) treated with aggressive chemotherapeutic regimens: results from the International Burkitt Lymphoma Collaborative Group [abstract]. Blood. 2005;106. Abstract #928.","DOI":"10.1182\/blood.V106.11.928.928"},{"key":"2019111709210457900_R25","doi-asserted-by":"crossref","unstructured":"Thomas DA, Cortes J, O\u2019Brien S, et al. Hyper-CVAD program in Burkitt\u2019s-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999;17:2461\u20132470.","DOI":"10.1200\/JCO.1999.17.8.2461"},{"key":"2019111709210457900_R26","doi-asserted-by":"crossref","unstructured":"Thomas DA, Faderl S, O\u2019Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569\u20131580.","DOI":"10.1002\/cncr.21776"},{"key":"2019111709210457900_R27","doi-asserted-by":"crossref","unstructured":"Kujawski LA, Longo WL, Williams EC, et al. A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like lymphomas. Cancer Invest. 2007;25:87\u201393.","DOI":"10.1080\/07357900701205507"},{"key":"2019111709210457900_R28","doi-asserted-by":"crossref","unstructured":"Song KW, Barnett MJ, Gascoyne RD, et al. Haematopoietic stem cell transplantation as primary therapy of sporadic adult Burkitt lymphoma. Br J Haematol. 2006;133:634\u2013637.","DOI":"10.1111\/j.1365-2141.2006.06080.x"},{"key":"2019111709210457900_R29","doi-asserted-by":"crossref","unstructured":"Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667\u2013678.","DOI":"10.1038\/sj.bmt.1703891"},{"key":"2019111709210457900_R30","doi-asserted-by":"crossref","unstructured":"Ribera JM, Oriol A, Esteve J, et al. Specific intensive chemotherapy plus rituximab for advanced Burkitt\u2019s lymphoma or leukemia in HIV positive and negative adult patients [abstract]. Blood. 2007;110. Abstract #1010.","DOI":"10.1182\/blood.V110.11.3448.3448"},{"key":"2019111709210457900_R31","doi-asserted-by":"crossref","unstructured":"Dunleavy K, Pittaluga S, Janik J, et al. Novel treatment of Burkitt lymphoma with dose-adjusted EPOCH-rituximab: preliminary results showing excellent outcome [abstract]. Blood. 2006;108. Abstract #774.","DOI":"10.1182\/blood.V108.11.2736.2736"},{"key":"2019111709210457900_R32","doi-asserted-by":"crossref","unstructured":"Blinder VS, Chadburn A, Furman RR, Mathew S, Leonard JP. Improving outcomes for patients with Burkitt lymphoma and HIV. AIDS Patient Care STDS. 2008;22:175\u2013187.","DOI":"10.1089\/apc.2007.0124"},{"key":"2019111709210457900_R33","doi-asserted-by":"crossref","unstructured":"Galicier L, Fieschi C, Borie R, et al. Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma\/leukemia: a prospective study. Blood. 2007;110:2846\u20132854.","DOI":"10.1182\/blood-2006-10-051771"},{"key":"2019111709210457900_R34","doi-asserted-by":"crossref","unstructured":"Hoffmann C, Wolf E, Wyen C, et al. AIDS-associated Burkitt or Burkitt-like lymphoma: short intensive polychemotherapy is feasible and effective. Leuk Lymphoma. 2006;47:1872\u20131880.","DOI":"10.1080\/10428190600685467"},{"key":"2019111709210457900_R35","unstructured":"Dunleavy K, Little RF, Pittaluga S, et al. A prospective study of dose-adjusted EPOCH with rituximab in adults with newly diagnosed Burkitt lymphoma: a regimen with high efficacy and low toxicity. Ann Oncol. 2008;19:iv83."},{"key":"2019111709210457900_R36","doi-asserted-by":"crossref","unstructured":"Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106:1538\u20131543.","DOI":"10.1182\/blood-2005-04-1437"},{"key":"2019111709210457900_R37","doi-asserted-by":"crossref","unstructured":"Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer. 2008;113:117\u2013125.","DOI":"10.1002\/cncr.23522"},{"key":"2019111709210457900_R38","doi-asserted-by":"crossref","unstructured":"Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23:7013\u20137023.","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"2019111709210457900_R39","doi-asserted-by":"crossref","unstructured":"Hecht JL, Aster JC. Molecular biology of Burkitt\u2019s lymphoma. J Clin Oncol. 2000;18:3707\u20133721.","DOI":"10.1200\/JCO.2000.18.21.3707"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/341\/786582\/341_348ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2008\/1\/341\/786582\/341_348ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T17:29:12Z","timestamp":1589390952000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2008\/1\/341\/95852\/Burkitt-Lymphoma-in-Adults"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2008.1.341","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,1]]}}}